TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Mayo Clinic
M.D. Anderson Cancer Center
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
IRCCS San Raffaele
Mayo Clinic
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
City of Hope Medical Center
Roswell Park Cancer Institute
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Centre Henri Becquerel
Mayo Clinic
City of Hope Medical Center
Swiss Cancer Institute
Ohio State University Comprehensive Cancer Center
Bambino Gesù Hospital and Research Institute
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of Washington
University of Washington
City of Hope Medical Center
City of Hope Medical Center
GWT-TUD GmbH
Ohio State University Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
Institut Curie
Duke University
Ohio State University Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
University of Rochester
University Hospital Southampton NHS Foundation Trust
Children's National Research Institute
City of Hope Medical Center
University of Chicago
Samsung Medical Center